§ Mr. Tom ClarkeTo ask the Secretary of State for Health (1) what consultations have taken place with the National Institute for Clinical Excellence on the Donaldson Report on ME; [117423]
(2) what consultations have taken place with the Medical Research Council on the Donaldson Report on ME; [117424]
(3) what action the Government have taken on the Donaldson Report on ME; and if he will make a statement. [117425]
§ Dr. Ladyman[holding answer 9 June 2003]: In our response to the Independent Working Group's Report on chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in January 2002, we endorsed their view that there should be no doubt this is a chronic illness and that health and social care professionals should recognise it as such.
We have had discussions with the National Institute for Clinical Excellence on the conclusions of the report.
We also asked the Medical Research Council (MRC) to develop a research strategy for advancing biomedical and health services research on chronic fatigue syndrome CFS/ME.
The MRC published their research strategy for (CFS/ME) on 1 May 2003. The strategy will enable researchers and funders to develop research proposals on all aspects of this illness. It was developed by an independent research advisory group in response to a request from the Chief Medical Officer, and was informed by contributions from patients, carers, charities, researchers and clinicians via a consultation exercise in summer 2002.
The MRC has announced two initiatives in response to the strategy. One is a notice to the research community welcoming high quality proposals across the entire spectrum of CFS/ME research. The other is a scientific meeting to discuss the potential to use existing UK resources and infrastructures to undertake epidemiological studies in this country. In addition, the MRC has just announced funding (15 May 2003) for two trials that will look at the effectiveness of various treatments for CFS/ME. The results of these trials will help patients and their doctors to choose the best treatment. These complementary trials will assess a variety of treatments, and in doing so, will both help address important issues for those with CFS/ME.
163WThe first trial known as PACE ("Pacing, Activity and Cognitive Behaviour Therapy: A Randomised Evaluation) will make the first assessment of a treatment choice popular with patients called 'Pacing'. The second trial, known as FINE, ("Fatigue Intervention by Nurses Evaluation") will test two different treatments that are particularly suited to helping reach those who are too ill to attend a specialist clinic as patients will be treated by nurses in their own homes.
On May 12 2003, we announced that funding of £8.5 million would be provided to develop services for people with CFS/ME. In July 2003, health organisations will be invited to bid for development funds to set up centres of expertise to develop clinical care, support clinical research and expand education and training programmes for health care professionals and to establish satellite community multidisciplinary teams. The first phase of development will commence in April 2004.